𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Improvement in renal function in hepatorenal syndrome with N-acetylcysteine

✍ Scribed by Steve Holt; David Goodier; Richard Marley; David Patch; Andrew Burroughs; Bimbi Fernando; Kevin Moore

Book ID
117294389
Publisher
The Lancet
Year
1999
Tongue
English
Weight
67 KB
Volume
353
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Terlipressin improves renal function in
Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome
✍ Aleksander Krag; SΓΈren MΓΈller; Jens H. Henriksen; Niels-Henrik Holstein-Rathlou; πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 200 KB πŸ‘ 1 views

Patients with advanced cirrhosis and ascites are characterized by circulatory dysfunction with splanchnic vasodilatation and renal vasoconstriction, which often lead to ascites. The vasoconstrictor terlipressin improves renal function in hepatorenal syndrome (HRS). The aim of this study was to evalu

Lack of renal improvement with nonselect
Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome
✍ Florence Wong; Kevin Moore; Jasper Dingemanse; Rajiv Jalan πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 826 KB

Renal vasoconstriction is a key factor in the development of hepatorenal syndrome (HRS) and may be secondary to increased activities of endothelin-1, a potent renal vasoconstrictor. To assess the effects of tezosentan, a nonselective endothelin receptor antagonist, on renal function in patients with